In the September issue of Pharmaceutical Executive, Lev Gerlovin addresses four main questions that US drugmakers must answer to cope with the evolving payer landscape given rising drug prices. To read the article, click the link below.
Prioritising Alzheimer’s disease policy in Europe: Insights from oncology
However, current levels of policy development do not reflect the urgency for change, especially given the progress made in understanding the disease and new...